{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020806","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.338782+00:00","generated_at":"2026-06-15T04:55:56.415355+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvalent reports Q1 2023 net loss of $25.2M; NVL-655 Phase 1 data expected H2 2023","bullets":["Net loss of $25.2M ($0.44 per share) for Q1 2023.","Cash, cash equivalents and marketable securities of $450.5M; runway into H2 2025.","R&D expenses $22.1M, G&A expenses $8.1M for Q1 2023.","Preliminary dose-escalation data for NVL-655 (ALK inhibitor) from ALKOVE-1 trial expected H2 2023.","NVL-520 (ROS1) Phase 1 enrollment ongoing; NVL-330 (HER2) in IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020806","json":"https://secwatch.observer/filing/0000950170-23-020806.json","markdown":"https://secwatch.observer/filing/0000950170-23-020806.md","text":"https://secwatch.observer/filing/0000950170-23-020806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023020806/0000950170-23-020806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023020806/nuvl-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:55:56.415355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce543ce377b0aa37e47e1a4957b882149b29db7f","claim":"Nuvalent, Inc. reported the first quarter of 2023 results: net income Net loss for the first quarter of 2023 was $25.2 million, EPS $0.44 per share.","evidence_excerpt":"Net loss for the first quarter of 2023 was $25.2 million, or $0.44 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023020806/0000950170-23-020806-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $25.2 million"},{"label":"EPS","value":"$0.44 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}